The phase IV study for comparing the response of high-dose cytarabine therapy among the KIT mutation status in adult core binding factor acute myeloid leukemia. -JALSG CBF-AML209-KIT Study (CBF-AML209-KIT)- - The study for comparing the response of high-dose cytarabine therapy among the KIT mutation status in adult core binding factor acute myeloid leukemia.

Japan adult leukemia study group0 个研究点目标入组 200 人开始时间: 2010年4月2日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1)Secondary AML (2)The patients with the past history of hematopoietic disorder. (3)The patients who received the craniotomy. (4)The patients who received the total skull irradiation. (5)The patients who received the radiation therapy. (6)The patients who have been identified the cancer after the registration to the JALSG AML209-GS study. (7)The patients who have developed myocardial infarction or angina after the registration to the JALSG AML209-GS study. (8)The patients with cardiac dysfunction. (9)The patients with active gastric ulcer. (10)The patients with the uncontrollable ileus. (11)The patients with the diabetes mellitus. (12)The patients with active infection. (13)The patients in whom the HBV-reactivation have been observed. (14)Psycological patients.

发起方